复发难治急性髓系白血病靶向治疗研究进展

Progress of targeted therapy in relapsed/refractory acute myeloid leukemia

当前复发难治急性髓系白血病(AML)的治疗仍然具有挑战性,复发难治AML患者还没有标准的治疗方法。目前研究认为参与涉及小分子靶向治疗、免疫治疗和表观遗传治疗等新疗法的临床试验可能是最好的选择,但临床试验治疗的有效性和不良反应尚未得到广泛评估,患者的长期生存尚不清楚,所以复发难治AML患者的预后仍然很差。未来研究方向将集中在新颖、有效和有针对性的治疗组合,以及低毒性、个性化和精准化的治疗策略上。文章综述了复发难治AML靶向治疗研究的最新进展。

At present,the treatment of relapsed/refractory acute myeloid leukemia(AML)is still challenging,and there is no standard treatment for relapsed/refractory AML patients.Current research believes that participating in clinical trials involving small molecule targeted therapy,immunotherapy and epigenetic therapy may be the best choice,but the efficacy and toxicity of clinical trials have not been widely evaluated,and the long-term survival of patients is not clear,so the prognosis of relapsed/refractory AML is still very poor.The future direction of research will focus on novel,effective and targeted treatment combinations,and low toxicity,personalized and accurate treatment strategies.This article reviews the latest progress in targeted therapy for relapsed/refractory AML.